Press release from Companies
Publicerat: 2021-01-20 11:29:47
Copenhagen, Denmark, 20 January 2021 – FluoGuide A/S ("FluoGuide" or the "Company") releases financial calendar for 2021. Please note that the release date of the Year-end report 2020 has been changed to 26 January 2021 from 26 February 2021.
Financial calendar for 2021: Year-end report 2020 (Q4): 26 January 2021 For further information: About FluoGuide
Annual report 2020: 26 January 2021
Annual General Meeting: 9 February 2021
January – March 2021 (Q1): 26 May 2021
Half-year report (Q2): 25 August 2021
January - September 2021 (Q3): 24 November 2021
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is undertaking a proof-of-concept clinical trial (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma including glioblastoma.This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.
